The MV-NiV candidate is a live attenuated measles vector-based vaccine containing the Nipah virus G gene (Malaysia strain). MV-NiV is being developed at The Institute of Medical Science, University of Tokyo, for the prevention of Nipah virus infection. The vaccine was shown to induce humoral and cellular immune responses and to protect against a lethal Nipah virus infection in preclinical studies. A first-in-human study is planned to assess the safety and immunogenicity of MV-NiV in healthy non-exposed volunteers.